Anebulo Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.anebulo.com
- Introduction
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Observational Study of THC Concentrations in Acute Cannabinoid Intoxication
- Conditions
- Acute Cannabinoid Intoxication
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06017622
- Locations
- 🇺🇸
University of Colorado School of Medicine, Aurora, Colorado, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05282797
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, ZH, Netherlands